Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Explore REGENXBIO's RGX-121 gene therapy for Hunter syndrome, with an FDA decision due Nov 9, 2025. Click here to read my most recent analysis.